Share on StockTwits

JMP Securities hoisted their price objective on shares of EXACT Sciences (NASDAQ:EXAS) from $22.00 to $28.00 in a research note issued on Wednesday. JMP Securities’ price target suggests a potential upside of 30.66% from the stock’s previous close.

Shares of EXACT Sciences (NASDAQ:EXAS) opened at 21.43 on Wednesday. EXACT Sciences has a 1-year low of $9.53 and a 1-year high of $22.01. The stock’s 50-day moving average is $17.04 and its 200-day moving average is $14.67. The company’s market cap is $1.777 billion. EXACT Sciences also saw a large increase in short interest in August. As of August 15th, there was short interest totalling 26,442,496 shares, an increase of 4.9% from the July 31st total of 25,198,205 shares. Approximately 32.4% of the shares of the company are short sold. Based on an average trading volume of 2,400,773 shares, the days-to-cover ratio is currently 11.0 days.

EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Tuesday, July 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same quarter in the previous year, the company posted ($0.19) earnings per share. On average, analysts predict that EXACT Sciences will post $-1.14 earnings per share for the current fiscal year.

EXAS has been the subject of a number of other recent research reports. Analysts at Canaccord Genuity raised their price target on shares of EXACT Sciences from $21.00 to $23.00 in a research note on Tuesday. They now have a “buy” rating on the stock. Finally, analysts at Benchmark Co. upgraded shares of EXACT Sciences to a “buy” rating in a research note on Tuesday, August 12th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. EXACT Sciences currently has an average rating of “Hold” and an average target price of $21.00.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.